Insulet Corporation (PODD) valuation
Insulet P/E ratio history
Insulet trades at 28.1 times its earnings over the last twelve months and 21.0 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 45.2 (year to Dec 2024) to 81.7 (year to Dec 2025), with a median of 73.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $284.24 | $3.48 | 81.7 | 48.2 |
| Dec 31, 2024 | $261.07 | $5.78 | 45.2 | 69.1 |
| Dec 31, 2023 | $216.98 | $2.94 | 73.8 | 96.6 |
| Dec 31, 2022 | $294.39 | $0.07 | n/m | 308.9 |
| Dec 31, 2021 | $266.07 | $0.24 | n/m | 250.8 |
| Dec 31, 2020 | $255.63 | $0.10 | n/m | — |
| Dec 31, 2019 | $171.20 | $0.18 | n/m | — |
| Dec 31, 2018 | $79.32 | $0.05 | n/m | — |
| Dec 31, 2017 | $69.00 | — | n/m | — |
| Dec 31, 2016 | $37.68 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Insulet valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| InsuletPODD | $10.4B | 28.1 | 21.0 | 3.4 |
| Baxter InternationalBAX | $11.9B | — | 11.2 | 1.0 |
| RevvityRVTY | $17.5B | 75.1 | 27.9 | 6.0 |
| Zimmer BiometZBH | $18.3B | 22.9 | 10.8 | 2.2 |
| SterisSTE | $22.2B | 27.8 | 19.8 | 3.7 |
| DexcomDXCM | $31.1B | 32.4 | 27.3 | 6.1 |
| ResMedRMD | $33.4B | 20.9 | 18.6 | 5.9 |
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| Peer median | 27.8 | 19.2 | 4.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PODD financials · PODD returns
No forecast, no recommendation. This page describes Insulet Corporation from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.